ArticleFrontiers in cardiovascular medicine2026
Caveolin-1 levels associated with coronary artery disease in Chinese participants: a retrospective cohort study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Coronary artery disease (CAD) remains a leading cause of mortality globally, yet approximately 30% of CAD risk remains unexplained by conventional factors. Caveolin-1 (Cav-1) regulates endothelial function through inhibiting endothelial nitric oxide synthase and promoting LDL transcytosis. While genome-wide association studies linked CAV1 variants to CAD risk (OR 1.19-1.23), whether circulating Cav-1 serves as a clinical biomarker for CAD risk stratification remains unknown. Methods: This retrospective cohort study enrolled 160 participants (105 CAD patients, 55 controls) who underwent coronary angiography at Shanxi Provincial People's Hospital, China, from September 2024 to February 2025. CAD was defined as ≥50% stenosis in major coronary arteries. Serum Cav-1 levels were measured using ELISA. Multivariable logistic regression models adjusted for age, sex, lipids, and biomarkers evaluated Cav-1's independent association with CAD. Restricted cubic spline (RCS) analysis assessed dose-response relationships, and receiver operating characteristic (ROC) curves evaluated discriminative performance. Results: CAD patients exhibited significantly lower Cav-1 levels than controls (7.0 ± 2.7 vs. 8.5 ± 2.7 ng/mL, Conclusions: Circulating Cav-1 demonstrates an independent, linear inverse association with CAD risk in Chinese adults. Combined with albumin, Cav-1 achieves robust discriminative performance, suggesting potential utility for refined risk stratification beyond traditional risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.